Evaluate the safety, side effects and maximum tolerable dose of topical application of Antimicrobial Peptides: Pexiganan (MSI-78), Tilapia piscidin 4 (TP4), Melittin, Nisin-A and Omiganan (MX-226) on the skin of healthy volunteers to the treatment of Skin and Soft Tissue Infections.

Start Date22 Jul 2020

Sponsor / Collaborator

Mashhad University of Medical Sciences

NCT03688971 / Unknown statusPhase 2

A Phase 2, Randomized, Vehicle and Ketoconazole-Controlled, Evaluator-Blinded, Study to Explore the Efficacy, Pharmacodynamics and Safety of Omiganan 1.75% Topical Gel BID in Patients With Mild to Moderate Facial Seborrheic Dermatitis

To explore the efficacy and pharmacodynamic effects of omiganan topical gel in facial seborrheic dermatitis.

Start Date22 Oct 2018

Sponsor / Collaborator

Maruho Co., Ltd.

EUCTR2017-003106-41-NL / Unknown statusPhase 2

A phase 2, randomized, vehicle and ketoconazole-controlled, evaluator-blinded, study to explore the efficacy, pharmacodynamics and safety of omiganan 1.75% topical gel BID in patients with mild to moderate facial seborrheic dermatitis.

Start Date05 Sep 2018

Sponsor / Collaborator

Maruho Co., Ltd.

100 Clinical Results associated with Omiganan

100 Translational Medicine associated with Omiganan

100 Patents (Medical) associated with Omiganan

Literatures (Medical) associated with Omiganan

11 Nov 2024·ACS Biomaterials Science & Engineering

Omiganan-Based Synthetic Antimicrobial Peptides for the Healthcare of Infectious Endophthalmitis

Article

Author: Wang, Shuo ; Xin, Jingguo ; Ong, Zhan Yuin ; Wang, Yongjie ; Wu, Hong ; Zheng, Zhi ; Qu, Sheng

Bacterial endophthalmitis is a severe infection of the aqueous or vitreous humor of the eye that can lead to permanent vision loss. Due to the rapid emergence of antibiotic resistance and dose-limiting toxicities, the standard treatment of bacterial endophthalmitis via the intravitreal injection of broad-spectrum antibiotics remains inadequate. Membrane active cationic antimicrobial peptides (AMPs) have emerged as a promising class of effective and broad-spectrum antimicrobial agents with potential to overcome antibiotic resistance. In this work, we investigate, for the first time, the use of omiganan (IK-12), a 12-amino acid indolicidin derivative for the treatment of bacterial endophthalmitis. Additionally, IK-12 was used as a template to perform amino acid rearrangements, without altering the length or type of amino acids, to yield a series of new derivative AMPs with varying extents of secondary structure formation under membrane mimicking conditions. IK-12 and its derivatives demonstrated strong and broad-spectrum antibacterial activities against a panel of clinically isolated Gram-positive and Gram-negative bacteria, including methicillin-resistant Staphylococcus aureus commonly implicated in bacterial endophthalmitis. Interestingly, two of the new IK-12 derivatives, IP-12 and WP-12, showed lower geometric mean minimum inhibitory concentration and higher 50% hemolysis concentration values, which effectively translated into 2- to 3.4-fold higher bacterial selectivity than the parent IK-12. Furthermore, the intravitreal injection of IK-12, IP-12, and WP-12 in a rabbit model of MRSA-induced endophthalmitis led to considerably improved clinical presentation and reduced recruitment of inflammatory cells. In all, these results demonstrate the potential of IK-12 and its derivatives, IP-12 and WP-12, as promising candidates for the treatment of bacterial endophthalmitis.

01 Nov 2023·Asian Journal of Pharmaceutical Sciences

An infection-microenvironment-targeted and responsive peptide-drug nanosystem for sepsis emergency by suppressing infection and inflammation

Article

Author: Gai, Yongkang ; Fu, Daan ; Ye, Zhilan ; Liu, Xingxin ; Chang, Bingcheng ; Chen, Xu ; Liu, Jia ; He, Wei ; Yang, Chang

Sepsis is a life-threatening emergency that causes millions of deaths every year due to severe infection and inflammation. Nevertheless, current therapeutic regimens are inadequate to promptly address the vast diversity of potential pathogens. Omiganan, an antimicrobial peptide, has shown promise for neutralizing endotoxins and eliminating diverse pathogens. However, its clinical application is hindered by safety and stability concerns. Herein, we present a nanoscale drug delivery system (Omi-hyd-Dex@HA NPs) that selectively targets infectious microenvironments (IMEs) and responds to specific stimuli for efficient intervention in sepsis. The system consists of omiganan-dexamethasone conjugates linked by hydrazone bonds which self-assemble into nanoparticles coated with a hyaluronic acid (HA). The HA coating not only facilitates IMEs-targeting through interaction with intercellular-adhesion-molecule-1 on inflamed endotheliocytes, but also improves the biosafety of the nanosystem and enhances drug accumulation in primary infection sites triggered by hyaluronidase. The nanoparticles release dual drugs in IMEs through pH-sensitive cleavage of hydrazone bonds to eradicate pathogens and suppress inflammation. In multiple tissue infection and sepsis animal models, Omi-hyd-Dex@HA NPs exhibited rapid source control and comprehensive inflammation reduction, thereby preventing subsequent fatal complications and significantly improving survival outcomes. The bio-responsive and self-delivering nanosystem offers a promising strategy for systemic sepsis treatment in emergencies.

01 Apr 2023·Amino Acids

Rational design of stapled antimicrobial peptides

Review

Author: Zhu, YouZhuo ; Liu, HongYu ; Zheng, Heng ; You, YuHao

The global increase in antimicrobial drug resistance has dramatically reduced the effectiveness of traditional antibiotics. Structurally diverse antibiotics are urgently needed to combat multiple-resistant bacterial infections. As part of innate immunity, antimicrobial peptides have been recognized as the most promising candidates because they comprise diverse sequences and mechanisms of action and have a relatively low induction rate of resistance. However, because of their low chemical stability, susceptibility to proteases, and high hemolytic effect, their usage is subject to many restrictions. Chemical modifications such as D-amino acid substitution, cyclization, and unnatural amino acid modification have been used to improve the stability of antimicrobial peptides for decades. Among them, a side-chain covalent bridge modification, the so-called stapled peptide, has attracted much attention. The stapled side-chain bridge stabilizes the secondary structure, induces protease resistance, and increases cell penetration and biological activity. Recent progress in computer-aided drug design and artificial intelligence methods has also been used in the design of stapled antimicrobial peptides and has led to the successful discovery of many prospective peptides. This article reviews the possible structure-activity relationships of stapled antimicrobial peptides, the physicochemical properties that influence their activity (such as net charge, hydrophobicity, helicity, and dipole moment), and computer-aided methods of stapled peptide design. Antimicrobial peptides under clinical trial: Pexiganan (NCT01594762, 2012-05-07). Omiganan (NCT02576847, 2015-10-13).

News (Medical) associated with Omiganan

10 Nov 2022

·www.biospace.com

Comera Life Sciences Reports Financial Results for Third Quarter 2022 and Business Highlights

Extended and broadened its ongoing research collaboration with Regeneron, a leading U.S. biotechnology company Announces CLS-001 as subcutaneous formulation of vedolizumab, a currently marketed monoclonal antibody for the treatment of inflammatory bowel disease (IBD) WOBURN, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, today reported financial results for the quarter ended September 30, 2022 and provided a business update. “We are extremely pleased with our progress this quarter. We have made significant advancements in strengthening our internal pipeline, team and capabilities, highlighted by a recent extension and expansion of one of our noteworthy biotechnology partnerships,” said Jeffrey Hackman, Chairman and Chief Executive Officer of Comera. “We continue to execute on our long-term strategy to leverage our SQore™ platform to transform the delivery of biologics from intravenous to subcutaneous form, and achieve our mission of reducing healthcare costs and improving patient quality of life by offering treatments that support greater independence while also creating value for our shareholders.” 3Q 2022 and Recent Business Highlights Recently, Comera extended and broadened its ongoing research collaboration with Regeneron, a leading U.S. biotechnology company. The partnership includes a right to negotiate a license after further technical evaluation is complete. Today, Comera is introducing its lead pipeline candidate CLS-001 as a subcutaneous (SQ) formulation of vedolizumab, a currently marketed product for the treatment of IBD including Crohn’s disease and ulcerative colitis. Comera believes that a SQ formulation of vedolizumab could have significant advantages for patients and the healthcare system, compared to the current intravenous (IV) formulation. In July 2022, Comera announced favorable topline results from its SEQURUS-1 study. The results of this preclinical study provide supportive evidence of safety of Comera’s lead caffeine-based SQore excipient when administered as a SQ biologic drug product formulation with a monoclonal antibody (mAb). SEQURUS-1 demonstrated no evidence of local or systemic toxicity of caffeine when administered subcutaneously with ipilimumab, a mAb therapy that works to activate the immune system by targeting CTLA-4 to treat melanoma, in animals. Furthermore, a rapid clearance of caffeine was seen within eight hours from test animals, in line with modeled predictions. Initial data also demonstrate no evidence of caffeine impact on ipilimumab absorption. In August 2022, Comera announced entry into a purchase agreement with Arena Business Solutions Global SPC II, Ltd. (Arena) for up to $15 million of the Company’s common stock, with an option to increase to $30 million. The equity line of credit will be used to invest in Comera’s pipeline and proprietary SQore platform. Comera has the right to sell to Arena up to $15 million worth of shares, in its sole discretion, over a 36-month period subject to certain limitations. In October 2022, Comera announced the expansion of its Woburn, Mass. facility. The expanded facility spans over 5,000 square feet and includes additional laboratory space for research and development (R&D) activities as well as new executive offices. The increased footprint will allow the company to double its workforce in the coming years. In October 2022, Comera announced favorable safety and pharmacokinetic results from its SEQURUS-2 study. Together with the SEQURUS-1 study, the SEQURUS-2 data demonstrate no evidence of local or systemic toxicity of caffeine in animals when administered subcutaneously with ipilimumab. Additionally, the results establish that caffeine had no impact on ipilimumab half-life and no effect on pharmacokinetic data for both the IV and SQ groups. In November 2022, Comera appointed Janice Marie McCourt as Chief Business Officer. In her role at Comera, Ms. McCourt will be responsible for business development, including evaluation and execution of out-licensing, in-licensing and strategic transaction opportunities, and driving the execution of the Company’s commercial strategy. Ms. McCourt brings more than 30 years of biotechnology and pharmaceutical experience. Third Quarter 2022 Financial Results Comera reported revenues of $235 thousand for the three months ended September 30, 2022, compared to $88 thousand for the same period in 2021, with the increase primarily related to an increase in research activities performed under customer contracts. Cost of revenue totaled $61 thousand for the three months ended September 30, 2022, compared to $48 thousand for the same period in 2021. R&D expenses totaled $395 thousand for the three months ended September 30, 2022, compared to $264 thousand for the same period in 2021, with the increase primarily related to expansion of R&D activities and higher employee related expenses. General and administrative expenses totaled $2.3 million for the three months ended September 30, 2022, compared to $689 thousand for the same period in 2021, due primarily to an increase in expenses in connection with the Company’s growth and costs associated with transitioning to a public company. Comera reported a net loss attributable to common stockholders of $3.2 million, or $0.20 loss per share for the three months ended September 30, 2022, primarily driven by increased expenses to support the Company’s growth and public company related costs, as compared to a net loss of $914 thousand, or $6.34 loss per share, for the same period in 2021. Comera had $3.0 million in cash and receivables at September 30, 2022. About Comera Life Sciences Leading a compassionate new era in medicine, Comera Life Sciences is applying a deep knowledge of formulation science and technology to transform essential biologic medicines from intravenous (IV) to subcutaneous (SQ) forms. The goal of this approach is to provide patients with the freedom of self-injectable care, reduce institutional dependency and to put patients at the center of their treatment regimen. To learn more about the Comera Life Sciences mission, as well as the proprietary SQore™ platform, visit . Forward-Looking Statements This press release includes “forward-looking statements” within the meaning of the federal securities laws. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this document, including, but not limited to: risks that the recently completed business combination disrupts the Company’s current plans and ability to retain its employees; the Company’s ability to maintain the listing of its securities on the Nasdaq Capital Market; the effect of the COVID-19 pandemic on the Company’s business; the price of the Company’s securities may be volatile due to a variety of factors, including changes in the competitive and highly regulated industries in which the Company plans to operate, variations in performance across competitors, changes in laws and regulations affecting the Company’s business and changes in the capital structure; the ability to implement business plans, forecasts, and other expectations and identify and realize additional opportunities; the risk of downturns and the possibility of rapid change in the highly competitive industry in which the Company operates; the risk that the Company and its current and future collaborators are unable to successfully develop and commercialize the Company’s products or services, or experience significant delays in doing so; the risk that we will be unable to continue to attract and retain third-party collaborators, including collaboration partners and licensors; the risk that the Company may never achieve or sustain profitability; the risk that the Company will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk that the Company experiences difficulties in managing its growth and expanding operations; the risk that third-party suppliers and manufacturers are not able to fully and timely meet their obligations; the risk that the Company is unable to secure or protect its intellectual property; the risk that the Company is unable to secure regulatory approval for its product candidates; general economic conditions; and other risks and uncertainties indicated in the Current Report on Form 8-K filed with the SEC on May 25, 2022 under “Risk Factors” and in other filings that have been made or will be made with the SEC. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of Comera’s Current Report on Form 8-K filed with the SEC on May 25, 2022 and other documents filed by Comera from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Comera assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Comera can give no assurance that it will achieve its expectations. Contacts Comera Investor John Woolford ICR Westwicke John.Woolford@westwicke.com Comera Press Jon Yu ICR Westwicke ComeraPR@westwicke.com

Financial StatementExecutive ChangeClinical ResultLicense out/in

20 Oct 2022

·endpts.com

Manufacturing roundup: Hikma, Lilly US manufacturing sites hit with 483s; GAO says HHS should address stockpile risks

The FDA has handed down inspection reports to several manufacturing sites in New Jersey, revealing a range of quality control issues. The 483 inspection report for Hikma Injectables’ outsourcing facility in Dayton, NJ, notes three observationss from an inspection from late May to early June of this year. The inspection reveals that the “airborne particulate monitoring program for aseptic operations” was not designed to support the quality of drug products meant to be sterile and was not monitoring airborne particulates correctly. The FDA noted on multiple occasions that “particle Counters” were not being directed into the flow of air. The FDA also notes that some drug products were not properly tested to determine an expiration date, with several products highlighted for not having those results. Another 483 spells out the inspection details at an Eli Lilly facility in Branchburg, NJ. Several weeks ago , an inspection in July by the US regulator revealed several issues surrounding quality control at the Lilly site. The two-page report now reveals “unknown debris” in the building and a tank not being “adequately controlled pending satisfactory completion of evaluation by the quality unit.” The site also failed to document and investigate any deviations from lab procedures. Specifically, the report states that the site did not investigate the impact, root cause, and corrective actions when an Analyst in a redacted QC lab had failed to follow procedure before starting system flow during cleaning. The Branchburg site has been on the government’s radar for a while, the DOJ slapping it with a subpoena requesting additional documentation on its work in Branchburg. Meanwhile, the whistleblower brought the company to court in New Jersey to seek damages after revealing a wide range of quality control failures dating back to 2018. HHS should better manage inventory gaps risks within the national stockpile — GAO report While the HHS has been busy filling the Strategic National Stockpile (SNS) with vaccines to counter recent outbreaks, the Government Accountability Office (GAO) has chimed in on the potential gaps and risks in the SNS. The report says that from 2015 through 2019, the stockpile used a “multi-step process involving interagency experts, resulting in annual SNS reviews with inventory recommendations,” but stopped when it underwent reorganization. Annual reviews were not completed in 2020 through 2022. The report states that: HHS has since completed reviews to inform inventory decisions for fiscal years 2023 and 2024. However, these reviews did not meet most statutory requirements—such as by including the amount of additional medical countermeasures procured— because HHS did not update its procedures to account for changes enacted in 2019. Until HHS updates its procedures, the agency risks not meeting the statutory requirements designed to give Congress additional information about the SNS inventory. The SNS has been given $5 billion to keep countermeasures on hand for potential anthrax and smallpox outbreaks, and the GAO’s analysis shows that most medical countermeasure types were acquired but often not in the recommended quantities. “HHS officials noted that gaps in quantities are due to budget constraints and acknowledge these gaps present risks. However, the reviews lack key information needed for managing these risks and communicating them to stakeholders, including to Congress,” the report points out. While the SNS was granted $6.1 billion in Covid-19 relief funds for supplies for the stockpile that significantly increased the amount of certain medical countermeasures, with most of the funding going toward ventilators and personal protective equipment. The GAO is making several recommendations to HHS including a review being conducted following statuary requirements, such as “descriptions of the responsibilities of interagency partners.” The GAO also recommends that the assistant secretary for preparedness and response should develop an approach for “ensuring that medical countermeasures under consideration for SNS procurement receive the same consideration regardless of whether they received development funding from BARDA.” The agency suggests finding a way to manage the risks associated with the gaps between inventory levels and the recommended quantities, and to report risks upon inspection. WHO reports shortage of Cholera vaccine, recommends a change in strategy The World Health Organization (WHO) reported that a strained global supply of cholera vaccines forced the hand of the body that manages the emergency supply of vaccines, the International Coordinating Group (ICG). The organization has suspended the use of two-dose vaccination regimens for cholera and instead will switch to a single dose. This will allow vaccines to last longer while instances of cholera outbreaks have been on the rise according to the WHO with nations such as Haiti, Syria and Malawi experiencing outbreaks this year. WHO stated that the one-dose approach can be effective although the exact length of the protection is limited and is lower in children. It is estimated that of the 36 million doses to be made this year, 24 million have been shipped out mainly to react to outbreaks. The ICG has been approved to get an additional 8 million doses. The WHO also notes that manufacturers are working at max capacity but there is currently no short-term solution to boost production. “The temporary suspension of the two-dose strategy will allow the remaining doses to be redirected for any needs for the rest of the year,” the WHO report said. Grifols opens new manufacturing site in Dublin Plasma medicine manufacturer Grifols is following in the footsteps of other major pharma on the Emerald Isle and capped off an expansion. The company reported that it opened a new 183,000-square-foot albumin manufacturing plant in Dublin, adding to Grifols’ presence in its Grange Castle facilities. The site will aim to triple the filling capacity of the production of its “FlexBag” container. “This new magnificent Dublin manufacturing facility, which incorporates Grifols industry-leading engineering, is indicative of this company’s commitment to investing in essential plasma-medicine infrastructure globally to treat more patients around the world,” said Grifols’ co-CEOs Víctor Grifols Deu and Raimon Grifols Roura, in a statement . The cost of the expansion and the headcount were not disclosed, but the company invested more than €300 million into its Irish operations since 2012 when it first established a presence there. Japanese cell therapy startup nets manufacturing partner A startup in the cell therapy space has netted a manufacturer for its eye disease drug candidate. Cellusion, a startup centered on using cells to treat disease in the eye, is partnering with the CDMO Minaris Regenerative Medicine to manufacture Cellusion’s candidate CLS001 which is aimed to treat bullous keratopathy, a disease that can cause blindness. According to the letter of intent, Cellusion and Minaris will develop the manufacturing process of the candidate, with Minaris’ operations in Allendale, NJ, “performing process optimization to meet requirements from the FDA.” Financial details of the deal or a timeline for the product to be finished were not disclosed. “It is exciting for Minaris Regenerative Medicine to be part of advancing a potential solution to corneal blindness, a widespread need, and we look forward to leveraging our extensive development resources to support Cellusion. We hope to position Cellusion well for its next clinical trial and potentially further support them in their manufacturing needs,” said Minaris CEO Hiroto Bando, in a statement .

Cell TherapyVaccine

12 Oct 2022

·www.biospace.com

Cellusion and Minaris Regenerative Medicine, a member of Showa Denko Materials, Enter into Business Alliance for the Manufacturing of CLS001 for a Corneal Endothelial Cell Regenerative Therapy

TOKYO--(BUSINESS WIRE)-- Cellusion Inc. (CEO: Shin Hatou, M.D. Ph.D., “Cellusion”), a Japanese regenerative medicine startup aiming to solve the global corneal transplant waiting list problem with a unique differentiation induction method from iPS cells to Corneal Endothelial Cell Substitute from iPS Cells (CECSi Cells) for bullous keratopathy novel treatment (PJ code: CLS001), and Minaris Regenerative Medicine, LLC (CEO: Hiroto Bando, Ph.D. MBA, “Minaris”), a leading global contract and development manufacturing organization (“CDMO”) and a member of Showa Denko Materials Co., Ltd. (CEO: Hidehito Takahashi, “Showa Denko Materials”), today announced Letter of Intent (“LOI”) of the Manufacturing of CLS001 for a Corneal Endothelial Cell Regenerative therapy in the United States. This press release features multimedia. View the full release here: Under the LOI, Cellusion and Minaris will develop the manufacturing process of Cellusion’s leading program, CLS001, a novel regenerative medicine product for bullous keratopathy treatment. Minaris’ Allendale, New Jersey team will perform process optimization to meet requirements from the FDA. “We are very enthusiastic to have the partnership with Minaris, a well-established regenerative medicine partner with over 20 years experiences including the predecessor companies, Progenitor Cell Therapy and Hitachi Chemical, and one of the leading CDMOs in the U.S. since the dawn of the field,” said Shin Hatou, M.D. Ph.D., CEO of Cellusion. “Together, we make our best efforts to develop the robust manufacturing process of CLS001 for patients suffering from bullous keratopathy due to the cornea donor shortage all over the world.” Hiroto Bando, Ph.D. MBA, CEO of Minaris said “It is exciting for Minaris Regenerative Medicine to be part of advancing a potential solution to corneal blindness, a widespread need, and we look forward to leveraging our extensive development resources to support Cellusion. We hope to position Cellusion well for its next clinical trial and potentially further support them in their manufacturing needs.” According to the World Health Organization (WHO) report, in 2021, at least 1 billion near or distant vision impairment cases could have been prevented or has yet to be addressed globally. Blindness of the cornea is the fourth leading cause of blindness, and is one of the major causes of visual deficiency after cataract, glaucoma, and age-related macular degeneration. Most of the patients with corneal blindness need corneal transplantation to restore their sight, but only 180,000 corneal transplants are conducted every year due to severe donor cornea shortage issues. Cellusion is striving to solve this problem, and by doing so support the UN’s Sustainable Development Goals 3 to ensure healthy lives and promote well-being for all ages. Cellusion has announced that patient recruitment began for the Investigator-Initiated Study first-in-human study of CLS001 to initiate in 2022 at the Keio University Hospital. Cellusion has been preparing to start its clinical trial in Japan within a few years followed by global studies in the US and EU region. [About CLS001] In spite of the fact that more than 13 million waiting patients for potential blinding diseases such as Bullous Keratopathy, which can only be prevented by corneal transplantation, only about 180,000 corneal transplants are performed annually worldwide. The reason for such a large medical supply-demand gap generated is because current treatments require donor corneas, skilled corneal transplant ophthalmologists, and Eye Banks. Cellusion is developing CLS001, CECSi cells for Corneal Endothelial regeneration to cure Bullous Keratopathy which is applied to more than half of all cases of corneal transplantation. CLS001 is expected to replace the current supply limitations by combining “CECSi Cells made from iPS cells with excellent proliferative properties” and “a simple injection cell delivery procedure without needs of human expertise.” [About Minaris] Minaris is a global CDMO for cell and gene therapies as a member of Showa Denko Materials group. Minaris offers their clients high value clinical and commercial manufacturing services, development solutions, and technologies. Minaris is a pioneer in the field with more than 20 years’ experience providing high quality and reliability. The facilities in the US, Europe, and Asia allow Minaris to supply patients worldwide with life-changing therapies. For more information, please visit Connect with Minaris: Twitter: LinkedIn: [About Cellusion] Cellusion is a regenerative medicine startup born from the Department of Ophthalmology, Keio University School of Medicine in 2015. Cellusion aims to contribute to the improvement of health and well-being around the world by solving unmet medical needs in medicine with its cutting-edge cell therapy technologies, including a unique differentiation induction method from iPS cells to CECSi endothelial cells. Cellusion’s mission is to give the worldwide community a clear vision of the future with the cellular technology breakthrough. Company: Cellusion Inc. CEO: Shin Hatou, M.D., Ph.D. Headquarters: 8-6 Nihonbashi-Kobuna, Chuo, Tokyo 103-0024, JAPAN Founded: January 2015 URL: View source version on businesswire.com: Contacts Noriko Takada Cellusion Inc. takadanoriko@cellusion.jp +81-3-5843-1785 Luc St-Onge, Ph.D. Global Head of Sales and Marketing Minaris Regenerative Medicine GmbH press@rm.minaris.de +49-89-700-9608-0 For further information: please ask us through the contact form on our website. Source: Cellusion Inc. View this news release online at:

CollaborateCell Therapy

100 Deals associated with Omiganan

External Link

KEGG	Wiki	ATC	Drug Bank
D05262	-	-	DB06610

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Dermatitis, Atopic	Phase 2	NL	Cutanea Life Sciences, Inc.	25 Nov 2016
Condylomata Acuminata	Phase 2	NL	Cutanea Life Sciences, Inc.	06 Apr 2016
Vulvar intraepithelial neoplasia	Phase 2	NL	Cutanea Life Sciences, Inc.	21 Nov 2015
Rosacea	Phase 2	AU	Cutanea Life Sciences, Inc.	13 Aug 2015
Propionibacterium Acnes Infection	Phase 2	-	Global Gaming Technologies Corp.	01 Oct 2000
Bacteremia	Phase 2	US	Global Gaming Technologies Corp.	01 Sep 2000
Fungemia	Phase 2	US	Global Gaming Technologies Corp.	01 Sep 2000
Acne Vulgaris	Phase 2	US	Global Gaming Technologies Corp.	-
Acne Vulgaris	Phase 2	US	Global Gaming Technologies Corp.	-
Bullous keratopathy	Phase 2	JP	-	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02576847 (CTgov)	Phase 3	Rosacea	307	Omiganan	(zbibmrjxzb) = aeoclcwwbw vfsobudogx (ggtjduiijw, anszdwskub - iqwyydqboq) View more	-	06 Jul 2022

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis